PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
30.26%
Some net income increase while CRVO is negative at -33.81%. John Neff would see a short-term edge over the struggling competitor.
-2.10%
Negative yoy D&A while CRVO is 48.94%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
No Data
No Data available this quarter, please select a different quarter.
-20.34%
Both cut yoy SBC, with CRVO at -10.43%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
-263.50%
Both reduce yoy usage, with CRVO at -52.55%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14.17%
Both reduce yoy usage, with CRVO at -83.75%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-397.71%
Negative yoy while CRVO is 0.00%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
10.50%
Some CFO growth while CRVO is negative at -13.25%. John Neff would note a short-term liquidity lead over the competitor.
-802.66%
Negative yoy CapEx while CRVO is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.56%
We cut debt repayment yoy while CRVO is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
-100.00%
Negative yoy issuance while CRVO is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.